SURG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. SURG is in a clear downtrend (bearish moving-average stack and negative MACD), and the recent equity offering at $1.25 signals dilution/financing need while the latest quarter shows severely negative profitability and margin deterioration. Although the stock looks short-term oversold near support ($1.134) and options positioning is call-heavy (bullish tilt), there is no Intellectia buy signal to prioritize and the setup is still trend-against. For an impatient buyer unwilling to wait, the odds favor more chop/downside than a clean reversal—avoid new entries here; if you own it, this is a sell/trim rather than add.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms sustained downside momentum. MACD histogram is negative (-0.0546) but contracting, implying selling pressure is easing (possible dead-cat bounce potential, not a confirmed reversal). RSI_6 at ~22.6 indicates oversold conditions, which can produce short bounces, but oversold in a downtrend is not a reliable buy signal without confirmation. Key levels: price ~1.14–1.15 is sitting just above S1 at 1.134 (near-term line in the sand). A break below 1.134 increases risk toward S2 at 0.932. Upside reclaim levels: pivot 1.46, then R1 1.787. Pattern-based outlook provided: ~80% chance of -0.99% next day, then +2.45% next week, +3.97% next month—near-term risk still skewed negative.
Intellectia Proprietary Trading Signals
closed public offering of 2M shares at $1.25, raising ~$2.5M for service expansion. Short-term oversold technical condition near support (1.
could fuel a bounce if buyers defend that level. Options positioning is call-heavy (bullish tilt).
in the near term. Clear bearish trend (MA stack bearish, MACD below zero) increases probability that any bounce is sold. High IV reflects uncertainty and potential for sharp adverse moves. No hedge fund/insider accumulation trend noted (both neutral).
Latest quarter: 2025/Q3. Revenue surged to $18.68M (+291.65% YoY), showing strong top-line growth, but profitability deteriorated meaningfully: net income was -$7.49M (more negative YoY by -47.54%), EPS -$0.38 (down -47.95% YoY). Gross margin collapsed to -14.92% (down -91.23% YoY), indicating severe cost/price pressure or one-time impacts; this is a major red flag because growth is not translating into healthy unit economics.
No analyst rating or price target change data was provided, so there is no confirmed recent trend in Wall Street ratings/targets. In absence of coverage signals, the practical pro/con read is: Pros—explosive revenue growth and potential expansion narrative. Cons—deepening losses, negative gross margin, and dilution risk dominate the current investability picture, which is why the risk/reward is not attractive for an impatient entry today.
